DE69622031D1 - INDOLDERIVATE ALS cGMP-PDE INHIBITOREN - Google Patents
INDOLDERIVATE ALS cGMP-PDE INHIBITORENInfo
- Publication number
- DE69622031D1 DE69622031D1 DE69622031T DE69622031T DE69622031D1 DE 69622031 D1 DE69622031 D1 DE 69622031D1 DE 69622031 T DE69622031 T DE 69622031T DE 69622031 T DE69622031 T DE 69622031T DE 69622031 D1 DE69622031 D1 DE 69622031D1
- Authority
- DE
- Germany
- Prior art keywords
- pct
- cgmp
- pde inhibitors
- indolder derivatives
- sec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9507432.4A GB9507432D0 (en) | 1995-04-10 | 1995-04-10 | Novel compounds |
GBGB9512560.5A GB9512560D0 (en) | 1995-06-21 | 1995-06-21 | Novel compounds |
GBGB9516136.0A GB9516136D0 (en) | 1995-08-07 | 1995-08-07 | New Use |
AUPN8294A AUPN829496A0 (en) | 1996-02-27 | 1996-02-27 | Novel compounds |
PCT/JP1996/000892 WO1996032379A1 (en) | 1995-04-10 | 1996-04-02 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69622031D1 true DE69622031D1 (de) | 2002-08-01 |
DE69622031T2 DE69622031T2 (de) | 2002-12-12 |
Family
ID=27424407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69622031T Revoked DE69622031T2 (de) | 1995-04-10 | 1996-04-02 | INDOLDERIVATE ALS cGMP-PDE INHIBITOREN |
Country Status (11)
Country | Link |
---|---|
US (1) | US6069156A (de) |
EP (1) | EP0820441B1 (de) |
JP (1) | JPH11503445A (de) |
KR (1) | KR100430059B1 (de) |
AT (1) | ATE219765T1 (de) |
CA (1) | CA2217707A1 (de) |
DE (1) | DE69622031T2 (de) |
ES (1) | ES2175079T3 (de) |
IL (1) | IL117848A0 (de) |
TW (1) | TW420663B (de) |
WO (1) | WO1996032379A1 (de) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996020925A1 (fr) * | 1995-01-06 | 1996-07-11 | Toray Industries, Inc. | Derive heterocyclique benzocondense et son utilisation |
PL328519A1 (en) * | 1996-02-19 | 1999-02-01 | Japan Tobacco Inc | Antidiabetic therapeutic agent |
CA2258728C (en) | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
US6713645B1 (en) * | 1996-10-30 | 2004-03-30 | Eli Lilly And Company | Substituted tricyclics |
JP2002509553A (ja) * | 1997-10-27 | 2002-03-26 | 藤沢薬品工業株式会社 | cGMP−PDE阻害剤としての三環式化合物 |
US6410584B1 (en) | 1998-01-14 | 2002-06-25 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells with indole derivatives |
AU2641199A (en) * | 1998-02-27 | 1999-09-15 | Kyowa Hakko Kogyo Co. Ltd. | Remedies for erectile dysfunction |
RU2217421C2 (ru) * | 1998-03-26 | 2003-11-27 | Шионоги & Ко., Лтд. | Производные индола, обладающие антивирусной активностью |
WO1999054284A1 (en) | 1998-04-20 | 1999-10-28 | Fujisawa Pharmaceutical Co., Ltd. | Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase |
US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
US6875575B1 (en) | 1998-11-25 | 2005-04-05 | Osi Pharmaceuticals, Inc. | Diagnostic methods for neoplasia |
US6025394A (en) | 1999-01-29 | 2000-02-15 | Cell Pathways, Inc. | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols |
US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
EP1243268A4 (de) * | 1999-12-14 | 2003-05-21 | Nippon Shinyaku Co Ltd | Medizinische zusammenstellung |
EP1316316B1 (de) * | 2000-09-06 | 2012-04-04 | Mitsubishi Tanabe Pharma Corporation | Zubereitungen zur oralen anwendung |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
AU2002230217B2 (en) * | 2001-02-15 | 2005-02-17 | Tanabe Seiyaku Co., Ltd. | Tablets quickly disintegrated in oral cavity |
EP1397130B1 (de) | 2001-06-20 | 2007-07-25 | Wyeth | Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1) |
TWI224101B (en) | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
EP2335700A1 (de) * | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C Virus Polymerase Inhibitoren mit heterobicylischer Struktur |
US20030162825A1 (en) * | 2001-11-09 | 2003-08-28 | Sepracor Inc. | D-amino acid oxidase inhibitors for learning and memory |
CA2465893A1 (en) | 2001-11-09 | 2003-05-22 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
US7208516B2 (en) * | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7276529B2 (en) * | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
EP1495016A2 (de) * | 2002-04-09 | 2005-01-12 | Astex Technology Limited | Heterocyclische verbindungen und deren verwendung als p38 map kinase modulatoren |
CA2481387A1 (en) * | 2002-04-12 | 2003-10-23 | Celgene Corporation | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
KR20050000400A (ko) * | 2002-04-12 | 2005-01-03 | 셀진 코포레이션 | 줄기 및 전구 세포 분화의 조절, 측정 및 이들의 용도 |
RU2296759C2 (ru) * | 2002-09-12 | 2007-04-10 | Ф.Хоффманн-Ля Рош Аг | N-замещенные 1н-индол-5-пропионовые кислоты, фармацевтическая композиция, содержащая эти соединения, и их применение (варианты) |
BR0316574A (pt) | 2002-12-10 | 2005-10-04 | Wyeth Corp | Derivados de ácido acético 3-carbonil-1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1) |
DE60324183D1 (en) | 2002-12-10 | 2008-11-27 | Wyeth Corp | Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1) |
ES2268480T3 (es) | 2002-12-10 | 2007-03-16 | Wyeth | Derivados del acido 3-alquilo- y 3-arilalquilo-1h-indol-1-il-acetico sustituidos como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1). |
UA80453C2 (en) | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
MXPA05006287A (es) | 2002-12-10 | 2005-09-08 | Wyeth Corp | Derivados de acido indoloxo-acetilaminoacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1). |
TW200418825A (en) | 2002-12-16 | 2004-10-01 | Hoffmann La Roche | Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives |
WO2004063156A1 (en) * | 2003-01-08 | 2004-07-29 | Biovitrum Ab | Novel indole derivates as fabp-4 inhibitors |
US7223785B2 (en) * | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7098231B2 (en) * | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7141600B2 (en) * | 2003-04-15 | 2006-11-28 | The Regents Of The University Of California | Small molecule inhibition of a PDZ-domain interaction |
EP1660427A4 (de) * | 2003-08-14 | 2006-12-20 | Asahi Kasei Pharma Corp | Substituiertes arylalkansäurederivat und dessen verwendung |
US7342039B2 (en) | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
US7163954B2 (en) | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
US7141592B2 (en) | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
US7446201B2 (en) | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
US7420083B2 (en) | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
US7268159B2 (en) | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
US7265148B2 (en) | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
US7332521B2 (en) | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
US7351726B2 (en) | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
US7582773B2 (en) | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
US7488747B2 (en) | 2003-12-29 | 2009-02-10 | Sepracor Inc. | Pyrrole and pyrazole DAAO inhibitors |
RS52931B (en) | 2004-02-20 | 2014-02-28 | Boehringer Ingelheim International Gmbh | VIRAL POLYMERASE INHIBITORS |
US7417063B2 (en) * | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
US7795295B2 (en) | 2004-07-01 | 2010-09-14 | The Regents Of The University Of California | Small molecule inhibition of PDZ-domain interaction |
WO2006019831A1 (en) * | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
BRPI0514549A (pt) | 2004-08-23 | 2008-06-17 | Wyeth Corp | ácidos de pirrol-naftila como inibidores de pai-1 |
CN101039936A (zh) | 2004-08-23 | 2007-09-19 | 惠氏公司 | 作为i-型纤溶酶原激活剂抑制剂(pai-1)调节剂用于治疗血栓形成和心血管疾病的唑基-萘基酸 |
JP5015154B2 (ja) * | 2005-08-12 | 2012-08-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルスポリメラーゼインヒビター |
EP1919866A2 (de) | 2005-08-17 | 2008-05-14 | Wyeth a Corporation of the State of Delaware | Substituierte indole und deren verwendung |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
US7960544B2 (en) * | 2005-12-16 | 2011-06-14 | Ironwood Pharmaceuticals, Inc. | Useful indole compounds |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
WO2007097197A1 (ja) | 2006-02-20 | 2007-08-30 | Astellas Pharma Inc. | アミド誘導体またはその塩 |
US8338416B2 (en) | 2006-03-16 | 2012-12-25 | Pharmacylics, Inc. | Indole derivatives as inhibitors of histone deacetylase |
US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
US7884124B2 (en) * | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
CA2660704A1 (en) | 2006-08-07 | 2008-02-14 | Ironwood Pharmaceuticals, Inc. | Indole compounds |
MX2010010334A (es) * | 2008-03-24 | 2010-10-08 | Celgene Corp | Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida. |
EP2427430B1 (de) | 2009-05-04 | 2014-09-10 | The Royal Institution for the Advancement of Learning/McGill University | 5-oxo-ete-rezeptorantagonistverbindungen |
AR084433A1 (es) | 2010-12-22 | 2013-05-15 | Ironwood Pharmaceuticals Inc | Inhibidores de la faah y composiciones farmaceuticas que los contienen |
US8987473B2 (en) | 2011-01-28 | 2015-03-24 | Sato Pharmaceutical Co., Ltd. | Ring-fused compound |
AU2012253402A1 (en) * | 2011-05-12 | 2013-05-02 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
EP3424904B1 (de) * | 2011-12-21 | 2020-12-02 | Allergan, Inc. | Verbindungen mit wirkung an mehreren prostaglandinrezeptoren mit einer allgemeinen entzündungshemmenden reaktion |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
EP2970177A1 (de) | 2013-03-15 | 2016-01-20 | Pfizer Inc. | Indolverbindungen zur ampk-aktivierung |
WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
EP3157520B1 (de) | 2014-06-23 | 2019-09-04 | Celgene Corporation | Apremilast zur behandlung einer lebererkrankung oder leberfunktionsanomalie |
EP3932914A1 (de) | 2015-03-13 | 2022-01-05 | Valo Health, Inc. | Alpha-cinnamid-verbindungen und zusammensetzungen als hdac8-inhibitoren |
AR105911A1 (es) | 2015-09-03 | 2017-11-22 | Forma Therapeutics Inc | Inhibidores de hdac8 bicíclicos fusionados [6,6] |
CN108602775B (zh) | 2016-01-14 | 2022-04-29 | 贝思以色列女会吏医学中心公司 | 肥大细胞调节剂及其用途 |
CN115919847B (zh) * | 2023-01-31 | 2024-05-28 | 中南大学 | 吲哚-3-醋酸甲酯在缓解放射诱导肺纤维化方面的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5234942A (en) * | 1984-10-19 | 1993-08-10 | Ici Americas Inc. | Heterocyclic amides and leucotriene antagonistic use thereof |
GB8609175D0 (en) * | 1986-04-15 | 1986-05-21 | Ici America Inc | Heterocyclic carboxamides |
GB9121776D0 (en) * | 1991-10-14 | 1991-11-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives and process for preparation thereof |
GB9126227D0 (en) * | 1991-12-10 | 1992-02-12 | Fujisawa Pharmaceutical Co | Ws63967 substances and a process for production thereof |
GB9204365D0 (en) * | 1992-02-28 | 1992-04-08 | Pfizer Ltd | Indoles |
CN1166169A (zh) * | 1994-07-27 | 1997-11-26 | 三共株式会社 | 用作毒蕈碱性受体别构效应物的杂环化合物 |
-
1996
- 1996-04-02 DE DE69622031T patent/DE69622031T2/de not_active Revoked
- 1996-04-02 KR KR1019970707126A patent/KR100430059B1/ko not_active IP Right Cessation
- 1996-04-02 EP EP96907750A patent/EP0820441B1/de not_active Revoked
- 1996-04-02 JP JP8530864A patent/JPH11503445A/ja not_active Ceased
- 1996-04-02 WO PCT/JP1996/000892 patent/WO1996032379A1/en not_active Application Discontinuation
- 1996-04-02 ES ES96907750T patent/ES2175079T3/es not_active Expired - Lifetime
- 1996-04-02 CA CA002217707A patent/CA2217707A1/en not_active Abandoned
- 1996-04-02 AT AT96907750T patent/ATE219765T1/de not_active IP Right Cessation
- 1996-04-02 US US08/930,597 patent/US6069156A/en not_active Expired - Fee Related
- 1996-04-08 IL IL11784896A patent/IL117848A0/xx unknown
- 1996-04-16 TW TW085104519A patent/TW420663B/zh active
Also Published As
Publication number | Publication date |
---|---|
EP0820441A1 (de) | 1998-01-28 |
ES2175079T3 (es) | 2002-11-16 |
TW420663B (en) | 2001-02-01 |
EP0820441B1 (de) | 2002-06-26 |
KR19980703726A (ko) | 1998-12-05 |
JPH11503445A (ja) | 1999-03-26 |
ATE219765T1 (de) | 2002-07-15 |
CA2217707A1 (en) | 1996-10-17 |
IL117848A0 (en) | 1996-08-04 |
US6069156A (en) | 2000-05-30 |
DE69622031T2 (de) | 2002-12-12 |
WO1996032379A1 (en) | 1996-10-17 |
KR100430059B1 (ko) | 2004-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69622031D1 (de) | INDOLDERIVATE ALS cGMP-PDE INHIBITOREN | |
FR2686084B1 (fr) | Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques. | |
ATE228507T1 (de) | Substituierte 6-phenylphenanthridine | |
MX9205046A (es) | 1h-imidazo-(4,5-c)quinolin-4-aminas 1-substituidas | |
TR200101398T2 (tr) | Pirolidin türevleri-CCR-3 reseptörü antagonistleri. | |
AP9801378A0 (en) | 9-amino-3- keto erythromycin derivatives. | |
SE9504661D0 (sv) | New compounds | |
MX9707431A (es) | Inhibidores de la proteina cinasa c. | |
ES2160949T3 (es) | Derivados de fenilen-sulfonamida sustituidos en meta. | |
UY26082A1 (es) | Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica | |
MX9702382A (es) | Nuevos derivados de pirimidona con actividad antifungica. | |
EP1140900A4 (de) | Pyrazol verbindungen und ihre verwendung | |
TR199802401T2 (xx) | Peptid olmayan G-CSF mimetikleri. | |
PT920426E (pt) | Novos derivados de tiazole com efeito inibidor de fosfodiesterase | |
TR200000153T2 (tr) | İl-5 inhibite eden 6-azaurasil türevleri. | |
AP9801377A0 (en) | Tricyclic erythromycin derivatives. | |
ES2120025T3 (es) | Derivados de xantina utilizados como antagonistas de receptores de adenosina a1. | |
PL320915A1 (en) | Derivatives of piperasino-2,5-dione as modulators of drug-fasteness in respect to many drugs | |
SE9504662D0 (sv) | New compounds | |
AP9801235A0 (en) | Erythromycin derivatives. | |
NO974687L (no) | Kondenserte <beta>-carboliner |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP |
|
8339 | Ceased/non-payment of the annual fee | ||
8331 | Complete revocation | ||
8363 | Opposition against the patent |